Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozanimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 known ✓ | P21453 | 20/20 | 1.00 |
| ▸ | S1PR5 known ✓ | Q9H228 | 2/20 | 1.00 |
| ▸ | S1PR2 | O95136 | 2/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 2/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 2/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozanimod SCHEMBL29691988 | 1.00 | S1PR1 (1.00) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL1413256 | 1.00 | S1PR1 (1.00) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL2195490 | 1.00 | S1PR1 (1.00) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL29560683 | 1.00 | S1PR1 (1.00) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL30948381 | 1.00 | S1PR1 (1.00) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL25306241 | 0.99 | S1PR1 (0.98) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL20569961 | 0.99 | S1PR1 (0.98) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL29405708 | 0.99 | S1PR1 (0.98) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| Ozanimod SCHEMBL30536287 | 0.99 | S1PR1 (0.98) | S1PR1S1PR2S1PR4S1PR3S1PR5 | |
| SCHEMBL2212803 | 0.96 | S1PR1 (0.93) | S1PR1S1PR2S1PR4S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3518922-B1 | COMPOUNDS AND METHODS FOR TREATING LUPUS | RECEPTOS LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-2498610-B2 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11465995-B2 | Crystal and salt forms of tricyclic compound and preparation process thereof | MEDSHINE DISCOVERY INC. (CN) | 2022-10-11 | — | — | US | disclosed |
| US-11278526-B2 | Compounds and methods for treating lupus | RECEPTOS LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-11207301-B2 | Sphingosine 1 phosphate receptor agonists for neuroprotection | RECEPTOS LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210340115-A1 | A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE | PHARMAZELL GMBH (DE) | 2021-11-04 | — | — | US | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-3406142-B1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | CELGENE INT II SARL (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-3741755-A1 | CRYSTAL AND SALT FORMS OF TRICYCLIC COMPOUND AND PREPARATION METHOD THEREOF | Shijiazhuang Sagacity New Drug Development Company, Ltd. (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200339553-A1 | CRYSTAL AND SALT FORMS OF TRICYCLIC COMPOUND AND PREPARATION PROCESS THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20130231326-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231326-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8362048-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362048-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362048-B2 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | RECEPTOS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102762100-A | Selective sphingosine-1-phosphate receptor modulators and chiral synthesis methods | RECEPTOS INC | 2012-10-31 | — | — | CN | disclosed |
| US-20110172202-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172202-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172202-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2011060392-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278526-B2 | Compounds and methods for treating lupus | S1PR1, S1PR2, SSB | S1PR1 1/4885S1PR5 6/4885S1PR2 2/4885 |
| US-20110172202-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR5 5/4885S1PR2 3/4885 |
| US-20210340115-A1 | A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE | IL4I1, DHPS, ALK | S1PR1 493/4885S1PR5 580/4885S1PR2 340/4885 |
| US-11465995-B2 | Crystal and salt forms of tricyclic compound and preparation process thereof | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR5 5/4885S1PR2 2/4885 |
| US-20200339553-A1 | CRYSTAL AND SALT FORMS OF TRICYCLIC COMPOUND AND PREPARATION PROCESS THEREOF | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR5 5/4885S1PR2 2/4885 |
| US-11207301-B2 | Sphingosine 1 phosphate receptor agonists for neuroprotection | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR5 5/4885S1PR2 2/4885 |
| US-20130231326-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR5 5/4885S1PR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.